For people struggling with obesity without diabetes, the SURMOUNT-1 trial showed that the highest dose of TIRZEPATIDE/Mounjaro produced an impressive 20.9% weight loss in 72 weeks, or an average of 52 pounds lost! In addition, more than one third of participants on the highest dose lost over 25% of their body weight, a weight loss range that gets close to the amount of weight loss seen after bariatric surgery and not previously seen with other anti-obesity medications. For comparison, the placebo-controlled group lost an average of only 3.1% with diet and lifestyle changes alone over the same time frame. While it is difficult to compare results across different studies, prior studies showed the next most impressive medication, Wegovy (generic: semaglutide), producing an average of 14.9% weight loss over a slightly shorter time frame.

Additional benefits in overall health were seen in this study as well. Over 95% of participants with prediabetes at the start of the study achieved normal blood sugar levels by the end of the study, compared with around 62% achieved by the placebo group with diet and exercise alone. There were also significant improvements in cholesterol levels, blood pressure and overall reported physical function for those on TIRZEPATIDE/Mounjaro compared to placebo.

For people with Type 2 Diabetes, the SURPASS-1 trial showed that the highest dose of TIRZEPATIDE/Mounjaro produced an average weight loss of 11%, or about 25 pounds, with an average a1c reduction of 2.3% over a 40 week period! While not a perfect comparison, prior studies on the highest dose of Wegovy (generic: semaglutide) showed that Wegovy produced an average of 9.6% weight loss and 1.6% reduction in A1c over 68 weeks in people with diabetes.

While there are no studies yet in the use of TIRZEPATIDE/Mounjaro for weight regain or sub-optimal weight loss after bariatric surgery, there are studies that show that other GLP-1 agonists are safe and effective to use for patients after bariatric surgery. We are successfully using TIRZEPATIDE/Mounjaro and others in this class to help with sub-optimal weight loss after bariatric surgery with impressive results.

As with any medication, side effects can occur on this medication. The most common side effects include nausea, diarrhea and constipation. Usually, these are mild-to-moderate and they usually improve over time. We recommend a slow escalation in dose on these medications to reduce any side effects and give your body time to adjust to the medication. We also recommend simple dietary strategies to improve side effects such as eating more slowly than you might usually, avoiding high fat, greasy foods and making sure to sip water throughout the day to stay hydrated.

While TIRZEPATIDE/Mounjaro will not cause hypoglycemia, or low blood sugar, on its own, it can cause low blood sugars when combined with medications such as insulins or sulfonylurea medications. Your healthcare provider will likely need to reduce your dose or discontinue insulins or sulfonylurea medications when you start TIRZEPATIDE/Mounjaro to avoid these risks. The great news is, insulins and sulfonylurea medications can actually cause weight gain, while TIRZEPATIDE/Mounjaro causes weight loss, so being able to reduce or eliminate the need for insulins and sulfonylurea medications is beneficial to overall health and weight control for those with Type 2 Diabetes!

In rare cases, pancreatitis has been reported with this class of medications and therefore your healthcare provider should counsel you on signs and symptoms of pancreatitis, however, this is not a typical side effect. People with a family history of medullary thyroid cancer or MEN-2 syndrome should not take this medication and those who have previously had pancreatitis should also avoid this class of medications.

TIRZEPATIDE/Mounjaro is a once weekly subcutaneous injection taken in the thigh, abdomen or upper arm that most patients can administer themselves. It comes in a single-dose pen with the medication dose already measured out and the needle already attached to be as user-friendly as possible. The needle is very small and medication is injected just under the skin. Most people report very little pain or discomfort with this injection, most describe it as similar to a small pinch. The initial dose is 2.5 mg weekly. The second month, the dose is increased to 5 mg weekly. The third and subsequent months at Precision, the dose is either 5 mg or 10 mg weekly depending on your personal goals, results, and budget.

Although the difficult to get brand name Mounjaro is very expensive with pricing for the low dosing at around $1100.00, we now offer the equally effective Tirzepatide at the starting price of only $400 (with cash discount). The second month of medication is only $500 (with cash discount)! And at the highest dose that we offer and the one where 50% of research study participants lost at least 20% of their body weight during the study, this monthly price is only $900! As always, we deliver superior products at a very good price so that you can achieve the results that you desire and deserve.